Skip to content
Review Open access

Flavonoids as multi-target agents in colorectal cancer: mechanistic insights and translational nanomedicine perspectives

2027 · Traditional Medicine Research · 0 citations · 108 references

Abstract

Colorectal cancer (CRC) remains a major global health challenge due to treatment resistance and adverse effects of conventional chemotherapy. Flavonoids, naturally occurring polyphenolic compounds, have emerged as promising multi-target candidates for CRC therapy. This review summarizes the mechanisms, pharmacokinetic challenges, and translational strategies of major flavonoids: quercetin, apigenin, epigallocatechin gallate, luteolin, baicalein, fisetin, naringenin, and genistein. Preclinical evidence shows that these compounds inhibit CRC initiation, progression, and metastasis by modulating key oncogenic pathways. Mechanistically, flavonoids induce mitochondrial apoptosis, inhibit angiogenesis, reverse epithelial-mesenchymal transition, and resensitize chemoresistant cells to standard agents like 5-fluorouracil, oxaliplatin, and irinotecan. Despite strong preclinical efficacy, clinical translation is limited by poor bioavailability, rapid metabolism and clearance, and dependence on supraphysiological in vitro concentrations. To overcome this translational gap, nanotechnology-based delivery systems are evaluated to improve stability, tissue targeting, and therapeutic efficacy. Finally, ongoing clinical evaluations, safety profiles, and combination strategies are highlighted to guide the translation of flavonoid research into effective, personalized CRC therapies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.